Borderline Personality Disorder

Borderline personality disorder (BPD) is a pervasive, long-standing pattern of instability in emotion regulation, interpersonal relationships, self-image, and impulse control, present by early adulthood and evident across a variety of personal and social contexts — not confined to a single relationship or situation. At its core, BPD is a disorder of emotion dysregulation: intense, rapidly shifting emotional states that are genuinely harder to control and slower to settle than in most people, arising from a real interaction between biological temperament and developmental environment (see Risk Factors). Framing BPD this way — as a real, biologically grounded disorder rather than a label for a "difficult" or "manipulative" patient — is itself one of the most clinically important things a pharmacist can do, and directly shapes how a patient engages with care.

BPD affects an estimated 1.6% of community adults over a 12-month period (lifetime prevalence up to about 5.9%), but is far more concentrated in clinical settings: roughly 6% of primary care patients, about 10% of psychiatric outpatients, and about 20% of psychiatric inpatients meet criteria.^[1] Two points anchor everything else in this chapter. First, structured, evidence-based psychotherapy — dialectical behavior therapy (DBT) foremost — is the only first-line treatment, endorsed by every current major guideline.^[2][3][4] Second, and just as important for a pharmacist to know explicitly: no medication is approved by Health Canada or the FDA for the treatment of BPD itself, and current guidance specifically recommends against using drug treatment as primary therapy or for individual symptoms/behaviours associated with the disorder — pharmacotherapy has a real but strictly adjunctive role, reserved for specific comorbid symptom clusters.^[2][5] This population also carries a genuinely elevated risk of self-harm and completed suicide, which every pharmacist interacting with these patients needs to be prepared to recognize and escalate appropriately (see Red Flags).^[6]

DSM-5-TR diagnostic pattern

A pervasive pattern of instability in interpersonal relationships, self-image, and affect, together with marked impulsivity, beginning by early adulthood and present in a variety of contexts, indicated by 5 or more of the following 9 features.^[1]

The biosocial model

The best-supported etiologic model frames BPD as arising from an ongoing transaction between an inborn emotional vulnerability and an invalidating developmental environment.^[7] Emotional vulnerability means a biological predisposition to unusually intense, easily triggered negative emotion with a slow return to baseline. An invalidating environment is one that persistently dismisses, punishes, or trivializes a child's emotional expression — telling a distressed child their reaction is wrong, excessive, or attention-seeking, rather than helping them learn to identify and regulate it. Neither factor alone reliably produces BPD; it is the ongoing interaction between the two across development that does; a child with the same temperament raised in a validating, emotionally responsive environment may never develop the disorder, and not every patient with BPD has an identifiable trauma history.^[7]

Course over time — a genuinely hopeful point

BPD was once assumed to be a lifelong, essentially untreatable condition. Long-term prospective follow-up data have overturned that assumption: about half of patients achieve full recovery (symptomatic remission plus good social and vocational functioning) within 10 years, and roughly 93% achieve at least a 2-year symptomatic remission — and once attained, this remission tends to be genuinely stable rather than a temporary lull.^[8] This is an important message to reinforce with patients directly: BPD responds to appropriate treatment, and the trajectory is not fixed.

Epidemiology and associated features

BPD is diagnosed roughly 3 times more often in women than men in clinical settings, but structured community studies suggest a more equal sex distribution — a gap that likely reflects referral and ascertainment patterns rather than a true difference in who develops the disorder.^[1] Symptoms most often become clinically prominent in adolescence or young adulthood. Comorbidity is the rule rather than the exception: mood disorders (major depressive disorder and bipolar disorder), anxiety disorders, PTSD, eating disorders (particularly bulimia nervosa), substance use disorders (present in roughly half of patients), and other personality disorders all occur at substantially higher rates in patients with BPD than in the general population.^[1]

• Genetic and temperamental vulnerability — twin and family studies suggest substantial heritability (commonly estimated around 40-50%), expressed as an inborn tendency toward high negative emotionality, impulsivity, and heightened, slow-to-resolve emotional reactivity.^[7]
• An invalidating developmental environment — a caregiving environment that persistently dismisses, punishes, or trivializes a child's emotional experience, rather than helping the child learn to identify and regulate it; this is the environmental half of the biosocial model and does not require overt abuse to have this effect.^[7]
• Childhood trauma — physical, sexual, or emotional abuse, and neglect, are reported at substantially higher rates in patients with BPD than in the general population, though a meaningful proportion of patients have no identifiable trauma history — trauma is a strong risk factor, not a diagnostic requirement.^[7]
• Early insecure or disorganized attachment — an inconsistent or frightening early caregiving relationship is a recognized contributor to the developmental pathway described above.
• A family history of BPD or other significant psychiatric illness — including mood disorders and substance use disorders, consistent with both a shared genetic vulnerability and a shared environmental pathway.
• Comorbid ADHD or other impulse-control difficulty in childhood — an early impulsivity/emotional-reactivity phenotype is one of the probable developmental pathways described in the biosocial model.^[7]

These factors are probabilistic, not deterministic — the biosocial model explicitly frames BPD as arising from an interaction of vulnerability and environment over time, not from any single risk factor in isolation, and patients should never be assumed to have a specific history (particularly abuse) simply because of the diagnosis.^[7]

Screening

The McLean Screening Instrument for Borderline Personality Disorder (MSI-BPD) is a widely used 10-item yes/no self-report tool that maps directly onto the 9 DSM-5-TR criteria above (affective instability, anger, impulsivity, abandonment fears, relationship instability, self-harm/suicidality, emptiness, identity disturbance, and stress-related dissociation/paranoia, with 2 items covering the impulsivity criterion). It is presented here as a teaching reference to the domains it screens, not as a live interactive calculator or a diagnostic instrument in its own right — a positive screen supports referral for formal assessment, not a diagnosis on its own.

Formal diagnosis

A confirmed BPD diagnosis requires a structured clinical assessment — ideally a semi-structured diagnostic interview such as the SCID-5-PD — performed by a clinician trained in personality disorder assessment. This is not something to be established from a screening tool or a single encounter, and it is not a pharmacist's role to diagnose it; the pharmacist's role is pattern recognition (the features in Recognize the Condition), appropriate referral for formal assessment when the pattern is suspected but undiagnosed, and safe, informed care once a diagnosis is established.

Differentiating BPD from commonly confused conditions

Investigations

There is no diagnostic laboratory test for BPD. A reasonable baseline work-up — thyroid function, CBC, and a substance-use history/screen — is appropriate to identify an organic or substance-induced contributor to mood or behavioural instability, particularly at first presentation or when the pattern is atypical, but this is adjunctive to the clinical assessment above, not diagnostic for BPD itself.

• Reduce self-harm and suicidal behaviour, and keep the patient safe — the highest-priority target given the mortality risk in this population.^[6]
• Improve the capacity to regulate intense emotion — the central mechanism this disorder disrupts, and the core target of every evidence-based psychotherapy covered in this chapter.
• Reduce other impulsive, self-damaging behaviours (substance use, unsafe sex, reckless spending or driving, binge eating).
• Improve interpersonal functioning and relationship stability, including reducing the frequency and intensity of the idealization-devaluation pattern.
• Build a more stable, coherent sense of identity and self-image over time.
• Treat comorbid conditions (mood disorders, anxiety disorders, PTSD, eating disorders, substance use disorders) on their own terms rather than assuming every symptom is "the personality disorder."
• Avoid iatrogenic harm from the care system itself — specifically, reflexive polypharmacy and crisis-only engagement without a coordinated, longitudinal plan (see Choose Initial Treatment and Common Errors).
• Build durable self-management and emotion-regulation skills the patient can use independently, rather than creating dependence on crisis-driven contact alone.
• Set the expectation explicitly: full symptomatic remission is a realistic, evidence-supported outcome for most patients over time, not a false promise.^[8]

No medication is approved or curative — pharmacotherapy is adjunctive only

When adjunctive pharmacotherapy is reasonable

Reserve pharmacotherapy for specific, identifiable target symptom clusters that persist despite an adequate trial of structured psychotherapy, or as a time-limited bridge while access to psychotherapy is arranged — never as routine or default treatment. Every trial should have an explicit target symptom, a defined reassessment date, and a plan to stop if that specific target does not improve (see Monitoring & Follow-Up and Common Errors).^[5]

Affective dysregulation / comorbid mood or anxiety symptoms a trial of an SSRI is reasonable when a comorbid depressive or anxiety disorder is present or clearly suspected — evidence for BPD-specific mood-lability benefit alone is weak and inconsistent, so treat this as managing the comorbidity, not as treating BPD itself.^[5]

Impulsivity / behavioural dyscontrol / anger a mood stabilizer (lamotrigine, topiramate, or divalproex) has modest, inconsistent trial evidence for this specific symptom cluster — evidence quality is low, and at least one large, more rigorous trial found no benefit for lamotrigine over placebo, so set expectations accordingly and reassess objectively.^[5]

Transient cognitive-perceptual or psychotic-like symptoms, or severe affective instability a low-dose atypical antipsychotic (aripiprazole, olanzapine, or quetiapine) has modest short-term trial evidence — reserve for this specific indication, use the lowest effective dose, and reassess regularly given the metabolic monitoring burden (see Drug Tables).^[5]

Avoid benzodiazepines real risk of disinhibition and paradoxical aggression in this population, dependence risk with an already elevated impulsivity/substance-use burden, and no evidence of core-symptom benefit — avoid routine or ongoing use.^[2][5]

Avoid reflexive polypharmacy stacking multiple unproven psychotropic agents over time, without a specific target symptom or a plan to stop an ineffective one, is a well-recognized and avoidable problem in BPD care — every agent needs its own justification and its own stopping rule.^[5][2]

Dialectical behavior therapy (DBT)

Developed specifically for BPD, DBT has the strongest evidence base of any single intervention, including genuine reductions in self-harm and suicide attempts across randomized trials.^[4] It combines 4 structured components, typically over about a year: weekly individual therapy, a weekly skills-training group teaching 4 skill modules (mindfulness, distress tolerance, emotion regulation, and interpersonal effectiveness), between-session phone coaching for in-the-moment skill use during a crisis, and a therapist consultation team that supports the treating clinicians themselves. One foundational DBT concept patients are taught is "Wise Mind" — the integration of "Reasonable Mind" (logical, fact-based thinking) and "Emotion Mind" (feeling-driven thinking) into a balanced state that draws on both. Understanding this concept helps a pharmacist recognize and reinforce the skills language a patient in DBT is already using.

The DBT "Wise Mind" concept: the overlap of Reasonable Mind and Emotion Mind. (BunnyPG, CC BY-SA 4.0, Wikimedia Commons)

Mentalization-based therapy (MBT)

MBT helps patients build the capacity to accurately reflect on their own and others' mental states — thoughts, feelings, and intentions — which is thought to reduce the misinterpretation-driven interpersonal crises common in BPD. It is typically delivered as combined individual and group therapy over about 18 months. An 8-year follow-up of the original randomized trial found that patients who received partial-hospitalization MBT remained meaningfully better than those who received treatment as usual, even years after the structured treatment itself had ended, though general social functioning remained impaired in both groups.^[12]

Schema-focused therapy

Identifies maladaptive early "schemas" or emotional "modes" (for example, an abandoned/abused child mode, an angry/impulsive child mode, a punitive-parent mode, and a detached-protector mode) and works to build a stable "healthy adult" mode able to manage them. In a head-to-head Dutch randomized trial, 3 years of schema-focused therapy outperformed transference-focused psychotherapy on BPD-specific and general psychopathology measures and on quality of life, with substantially lower treatment dropout.^[13]

General Psychiatric Management (GPM) / structured clinical management

A less resource-intensive, generalist model combining case management, structured clinical support, and psychoeducation, without requiring specialized DBT/MBT/schema-therapy certification. Trial evidence shows it performs comparably to specialized therapies for many patients, making it a genuinely reasonable option — not a fallback of last resort — where specialized programs are not locally available.^[4][12]

Crisis and safety planning

A written, collaboratively developed safety plan — personal warning signs, specific coping strategies, people and services to contact, and means restriction where relevant — is itself an active nonpharmacologic intervention, not paperwork. Review and update it regularly, and treat it as a living document the patient helps write, not one handed to them.

Stigma-aware, validating communication for pharmacy staff

BPD carries more clinician-level stigma than almost any other psychiatric diagnosis — language like "manipulative," "attention-seeking," or "difficult patient" is both inaccurate and actively harmful to care.^[9] Practical guidance for every pharmacy interaction:

• Validate the emotion behind the behaviour, even when the behaviour itself cannot be accommodated — for example, "I can see you're in a lot of pain right now" rather than dismissing or arguing with the presentation.
• Maintain consistent, predictable boundaries — inconsistency between staff members (one being lenient, another strict, on the same request) can itself trigger dysregulation; agree on a shared approach as a team.
• Do not take angry or dismissive statements personally — these often reflect the disorder's core interpersonal instability in the moment, not an accurate judgment of pharmacy staff.
• Never withhold standard, safe pharmacy care as an implicit "consequence" for a difficult interaction.
• Treat every self-harm disclosure as a genuine clinical symptom requiring the pharmacy's own compassionate, structured escalation response (see Red Flags) — never as a nuisance or bid for attention.^[9]
• Recognize splitting for what it is — a recognized symptom pattern (idealizing one staff member, devaluing another), not evidence that one staff member handled things correctly and another did not. Bring it to the team rather than personalizing or taking sides.

No medication is approved by Health Canada or the FDA for the treatment of borderline personality disorder itself, and medication is never a substitute for structured psychotherapy. Every row below is an adjunctive, symptom-cluster-targeted option only — see Choose Initial Treatment for when each is genuinely appropriate.

Pregnancy

Structured psychotherapy remains the preferred foundation of treatment throughout pregnancy and carries no reproductive risk. Avoid divalproex — a major teratogen associated with neural tube defects and neurodevelopmental impairment — and use topiramate only with real caution given an increased risk of oral clefts; confirm effective contraception before starting either in any patient of reproductive potential, and discuss this explicitly rather than assuming it has been covered elsewhere.^[5] If pharmacotherapy is genuinely needed an SSRI for a comorbid depressive or anxiety disorder is generally preferred, following the same principles as the Depression and Anxiety Disorders chapters. The postpartum period carries a genuinely elevated risk of symptom exacerbation for BPD specifically — schedule closer follow-up and reassess safety proactively rather than waiting for the patient to raise concerns; any concern for infant safety is a red flag requiring urgent escalation (see Red Flags).

Breastfeeding

Sertraline and other standard-dose SSRIs are generally considered compatible with breastfeeding. Lamotrigine and divalproex are used with infant monitoring where clinically necessary. Antipsychotics (aripiprazole, olanzapine, quetiapine) require an individualized risk-benefit discussion; confirm current guidance for the specific agent before continuing use while breastfeeding.

Adolescents

BPD traits and patterns can be recognized, and DBT adapted specifically for adolescents (DBT-A) has real supporting evidence — dismissing this presentation as "just a phase" delays care that is more effective the earlier it starts. A formal personality disorder diagnosis in a minor should be made by a clinician with specific training in adolescent assessment, but the symptom pattern itself should prompt referral regardless of whether a formal diagnosis has yet been made.

Older adults

Impulsivity and behavioural dyscontrol often attenuate with age, though affective instability and chronic emptiness can persist. Polypharmacy risk is higher in this group given concurrent chronic-disease medication — actively reassess whether any ongoing psychotropic still has a clear, current target symptom rather than continuing it by default.

Comorbid substance use disorder

Present in roughly half of patients with BPD, comorbid substance use disorder complicates both psychotherapy engagement and self-harm risk. Integrated, concurrent treatment of both conditions together is preferred over treating one and deferring the other. Use particular caution with any medication carrying its own dependence or disinhibition risk (see benzodiazepines, above) in this specific overlap population.

Renal and hepatic impairment

Dose-adjust lamotrigine, topiramate, and quetiapine for reduced renal function, and use divalproex with caution and closer monitoring in hepatic impairment given its own hepatotoxicity risk. Aripiprazole and olanzapine generally require less renal adjustment but should still be used cautiously and at a lower starting dose in significant hepatic impairment. Confirm specifics against each drug's own Drug Database entry or current product monograph.

• Ask directly and nonjudgmentally about self-harm and suicidal ideation at every relevant encounter — asking does not increase risk, and a direct question is far more useful than avoiding the topic out of discomfort.^[6]
• Track engagement with structured psychotherapy specifically — early dropout is common in this population and is itself a clinically meaningful signal warranting outreach, not simply "noncompliance" to be noted and left unaddressed.
• For any pharmacotherapy started, confirm it still has an explicit target symptom and a defined reassessment date; discontinue promptly if that specific target has not clearly improved within a reasonable trial, rather than letting it continue indefinitely by default or adding a further agent on top.^[5][2]
• Screen for and actively manage comorbid conditions (mood and anxiety disorders, eating disorders, substance use disorder) on an ongoing basis rather than attributing every new symptom to "the personality disorder."
• For divalproex: baseline and periodic liver function tests, CBC/platelets, and an explicit, repeated pregnancy-prevention discussion for anyone of reproductive potential.
• For any antipsychotic (aripiprazole, olanzapine, quetiapine), apply the same baseline and ongoing metabolic monitoring (weight, waist circumference, fasting glucose, lipids) used for any other antipsychotic — "low dose" does not exempt a patient from this monitoring.
• Reassess the overall diagnosis and formulation periodically rather than treating it as fixed — comorbidities evolve, and a substantial proportion of patients achieve sustained symptomatic remission over years; reinforce this realistic, hopeful trajectory with the patient directly rather than defaulting to chronic-illness framing.^[8]

1. Confirm the patient actually accessed a genuinely structured, evidence-based psychotherapy (DBT, MBT, schema-focused therapy, or GPM) rather than general supportive counselling before concluding that "treatment has failed" — access barriers (wait-lists, cost, availability) are common and should be actively addressed, including bridging options such as telehealth, before assuming the treatment itself did not work.
2. For an inadequate response within an active structured psychotherapy, reassess: whether the program is being delivered with reasonable fidelity/completeness, whether an untreated comorbidity (depression, substance use disorder, eating disorder) is blocking progress, and whether the patient remains in an ongoing unsafe environment or relationship undermining treatment.
3. For a pharmacotherapy trial that shows no benefit for its specific target symptom at an adequate dose and duration, taper and discontinue it — do not add a second unproven agent on top of an ineffective one.
4. For escalating or new self-harm/suicidality during treatment, immediately reassess and update the safety plan and consider a more intensive level of care (partial hospitalization, a specialized personality-disorder service, or crisis stabilization) rather than responding with a medication change alone.
5. For recurrent early dropout from a higher-intensity specialized program, consider starting instead with a lower-intensity, more accessible model (GPM/structured clinical management) to build engagement before attempting a more demanding specialized program again.
6. For persistent diagnostic uncertainty or poor response despite what appears to be adequate, specific treatment, reconsider the differential diagnosis table in Assessment & Diagnosis — an unrecognized bipolar disorder, complex PTSD, or an undiagnosed substance use disorder are common, treatable explanations for an apparent treatment failure.

• Using pejorative language — "manipulative," "attention-seeking," "difficult," or "borderline" used as an insult — in conversation or documentation; this is documented, harmful clinician-level stigma specific to this diagnosis.^[9]
• Starting or continuing medication as the first or sole treatment instead of referring for structured, evidence-based psychotherapy.
• Reflexive polypharmacy — stacking multiple unproven psychotropic agents over time without a specific, time-boxed target symptom and an explicit plan to stop an ineffective one.
• Prescribing or continuing benzodiazepines routinely, despite the real disinhibition, paradoxical-aggression, and dependence risk in this specific population.
• Dismissing repeated self-harm disclosures as attention-seeking rather than treating every disclosure as a genuine clinical symptom warranting a structured, compassionate response.
• Assuming a single "true" account of a staff conflict when a patient describes classic splitting — bring it to the team rather than personalizing it or silently taking sides.
• Withholding standard, safe pharmacy care as an implicit "consequence" for a difficult interaction.
• Diagnosing bipolar disorder (or BPD) from the phrase "mood swings" alone, without assessing actual episode duration and interpersonal trigger pattern.^[10]
• Missing an undertreated comorbidity (depression, anxiety, substance use disorder, eating disorder, PTSD) and attributing every new symptom to "the personality disorder."
• Prescribing divalproex to a patient of reproductive potential without an explicit teratogenicity and contraception discussion.
• Treating a clear adolescent BPD symptom pattern as "just typical teenage moodiness" and delaying referral, when earlier intervention is associated with a better long-term trajectory.
• Assuming the disorder is lifelong and untreatable — current long-term follow-up data show most patients achieve sustained symptomatic remission with appropriate treatment.^[8]

No medication in this table is approved by Health Canada or the FDA for borderline personality disorder itself. Every class below is adjunctive only, reserved for a specific comorbid symptom cluster, and should be started with an explicit target symptom and reassessment date. Select any drug name to open its complete Pharmasist Drug Database page.

SSRIs — for a comorbid mood or anxiety disorder

Dosed and monitored exactly as in the Depression and Anxiety Disorders chapters. Treats the comorbidity; evidence for a BPD-specific mood-lability benefit alone is weak and inconsistent.

Mood stabilizers/anticonvulsants — for impulsivity, anger, or affective instability

Modest, low-certainty trial evidence for this specific symptom cluster; at least 1 large, more rigorous trial found no benefit for lamotrigine over placebo. Confirm effective contraception before starting any of these in a patient of reproductive potential.

Low-dose atypical antipsychotics — for transient cognitive-perceptual symptoms or severe affective instability

Modest short-term trial evidence. Apply the same baseline and ongoing metabolic monitoring (weight, waist circumference, fasting glucose, lipids) used for any other antipsychotic indication — a low dose does not exempt a patient from this monitoring.

Agents to avoid for routine use

Included to make the avoid guidance explicit and easy to find, not because these are recommended.